Compare GITS & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GITS | CNSP |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | South Korea | United States |
| Employees | 5 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.3M |
| IPO Year | N/A | 2019 |
| Metric | GITS | CNSP |
|---|---|---|
| Price | $1.54 | $4.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 145.4K | 26.6K |
| Earning Date | 05-19-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.73 |
| 52 Week High | $7.09 | $10.59 |
| Indicator | GITS | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 41.25 | 46.43 |
| Support Level | $1.49 | $4.50 |
| Resistance Level | $2.83 | $5.61 |
| Average True Range (ATR) | 0.25 | 0.31 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 2.38 | 19.05 |
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.